ES2571055A1 - Conjugado amiloide y usos y procedimientos del mismo - Google Patents

Conjugado amiloide y usos y procedimientos del mismo

Info

Publication number
ES2571055A1
ES2571055A1 ES201630173A ES201630173A ES2571055A1 ES 2571055 A1 ES2571055 A1 ES 2571055A1 ES 201630173 A ES201630173 A ES 201630173A ES 201630173 A ES201630173 A ES 201630173A ES 2571055 A1 ES2571055 A1 ES 2571055A1
Authority
ES
Spain
Prior art keywords
conjugate
translation
procedures
machine
legally binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201630173A
Other languages
English (en)
Other versions
ES2571055B1 (es
Inventor
Barrio Manuel Sarasa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Araclon Biotech SL
Original Assignee
Araclon Biotech SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araclon Biotech SL filed Critical Araclon Biotech SL
Priority to ES201630173A priority Critical patent/ES2571055B1/es
Publication of ES2571055A1 publication Critical patent/ES2571055A1/es
Application granted granted Critical
Publication of ES2571055B1 publication Critical patent/ES2571055B1/es
Priority to ES17705112T priority patent/ES2747899T3/es
Priority to RU2018126395A priority patent/RU2712750C1/ru
Priority to SI201730100T priority patent/SI3390426T1/sl
Priority to PL17705112T priority patent/PL3390426T3/pl
Priority to CN201780011191.3A priority patent/CN108633278B/zh
Priority to JP2018537651A priority patent/JP6689993B2/ja
Priority to MX2018008885A priority patent/MX2018008885A/es
Priority to CA3012417A priority patent/CA3012417C/en
Priority to NZ744411A priority patent/NZ744411B2/en
Priority to PT177051125T priority patent/PT3390426T/pt
Priority to SG11201806158YA priority patent/SG11201806158YA/en
Priority to PCT/EP2017/053242 priority patent/WO2017140656A1/en
Priority to MYPI2018702695A priority patent/MY184763A/en
Priority to AU2017221070A priority patent/AU2017221070B2/en
Priority to KR1020187024580A priority patent/KR102301961B1/ko
Priority to DK17705112.5T priority patent/DK3390426T3/da
Priority to EP17705112.5A priority patent/EP3390426B1/en
Priority to BR112018016016-4A priority patent/BR112018016016A2/pt
Priority to IL260639A priority patent/IL260639B2/en
Priority to CONC2018/0007557A priority patent/CO2018007557A2/es
Priority to ZA2018/04842A priority patent/ZA201804842B/en
Priority to CL2018002004A priority patent/CL2018002004A1/es
Priority to US16/103,810 priority patent/US20190030127A1/en
Priority to US16/855,263 priority patent/US20200246430A1/en
Priority to US17/679,723 priority patent/US20220184178A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2872—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against prion molecules, e.g. CD230
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
    • C01F7/00—Compounds of aluminium
    • C01F7/02—Aluminium oxide; Aluminium hydroxide; Aluminates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Geology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Conjugado amiloide y usos y procedimientos del mismo. Conjugado que comprende al menos un péptido CisAβ(33-40) (SEQ ID NO: 1) y hemocianina de lapa californiana (KLH), caracterizado porque el agente entrecruzante que conecta cada uno de los componentes del conjugado es el éster de N-hidroxisuccinimida del ácido maleimido butírico (SM); composiciones que comprenden dicho conjugado y usos y procedimientos relacionados con las mismas.
ES201630173A 2016-02-15 2016-02-15 Conjugado amiloide y usos y procedimientos del mismo Active ES2571055B1 (es)

Priority Applications (26)

Application Number Priority Date Filing Date Title
ES201630173A ES2571055B1 (es) 2016-02-15 2016-02-15 Conjugado amiloide y usos y procedimientos del mismo
EP17705112.5A EP3390426B1 (en) 2016-02-15 2017-02-14 Amyloid conjugate and uses and methods thereof
BR112018016016-4A BR112018016016A2 (pt) 2016-02-15 2017-02-14 conjugado amiloide e seus usos e métodos
PCT/EP2017/053242 WO2017140656A1 (en) 2016-02-15 2017-02-14 Amyloid conjugate and uses and methods thereof
AU2017221070A AU2017221070B2 (en) 2016-02-15 2017-02-14 Amyloid conjugate and uses and methods thereof
SI201730100T SI3390426T1 (sl) 2016-02-15 2017-02-14 Amiloidni konjugat ter uporabe in postopki le-tega
PL17705112T PL3390426T3 (pl) 2016-02-15 2017-02-14 Koniugat amyloidowy jego zastosowania i sposoby otrzymywania
CN201780011191.3A CN108633278B (zh) 2016-02-15 2017-02-14 淀粉样蛋白缀合物及其用途和方法
JP2018537651A JP6689993B2 (ja) 2016-02-15 2017-02-14 アミロイドコンジュゲート並びにその使用及び方法
MX2018008885A MX2018008885A (es) 2016-02-15 2017-02-14 Conjugado amiloide y usos y procedimientos del mismo.
CA3012417A CA3012417C (en) 2016-02-15 2017-02-14 Amyloid conjugate and uses and methods thereof
NZ744411A NZ744411B2 (en) 2016-02-15 2017-02-14 Amyloid conjugate and uses and methods thereof
PT177051125T PT3390426T (pt) 2016-02-15 2017-02-14 Conjugado amiloide e suas utilizações e métodos
SG11201806158YA SG11201806158YA (en) 2016-02-15 2017-02-14 Amyloid conjugate and uses and methods thereof
ES17705112T ES2747899T3 (es) 2016-02-15 2017-02-14 Conjugado amiloide y usos y procedimientos del mismo
MYPI2018702695A MY184763A (en) 2016-02-15 2017-02-14 Amyloid conjugate and uses and methods thereof
RU2018126395A RU2712750C1 (ru) 2016-02-15 2017-02-14 Амилоидный конъюгат, его применения и способы
KR1020187024580A KR102301961B1 (ko) 2016-02-15 2017-02-14 아밀로이드 접합체 및 그의 용도 및 방법
DK17705112.5T DK3390426T3 (da) 2016-02-15 2017-02-14 Amyloidkonjugat samt dermed forbundne anvendelser og fremgangsmåder
IL260639A IL260639B2 (en) 2016-02-15 2018-07-17 Amyloid conjugate and its uses and methods
ZA2018/04842A ZA201804842B (en) 2016-02-15 2018-07-18 Amyloid conjugate and uses and methods thereof
CONC2018/0007557A CO2018007557A2 (es) 2016-02-15 2018-07-18 Conjugado amiloide y usos y procedimientos del mismo
CL2018002004A CL2018002004A1 (es) 2016-02-15 2018-07-24 Conjugado amiloide y usos y procedimientos del mismo
US16/103,810 US20190030127A1 (en) 2016-02-15 2018-08-14 Amyloid conjugate and uses and methods thereof
US16/855,263 US20200246430A1 (en) 2016-02-15 2020-04-22 Amyloid conjugate and uses and methods thereof
US17/679,723 US20220184178A1 (en) 2016-02-15 2022-02-24 Amyloid conjugate and uses and methods thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201630173A ES2571055B1 (es) 2016-02-15 2016-02-15 Conjugado amiloide y usos y procedimientos del mismo

Publications (2)

Publication Number Publication Date
ES2571055A1 true ES2571055A1 (es) 2016-05-23
ES2571055B1 ES2571055B1 (es) 2016-12-28

Family

ID=55970560

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201630173A Active ES2571055B1 (es) 2016-02-15 2016-02-15 Conjugado amiloide y usos y procedimientos del mismo
ES17705112T Active ES2747899T3 (es) 2016-02-15 2017-02-14 Conjugado amiloide y usos y procedimientos del mismo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17705112T Active ES2747899T3 (es) 2016-02-15 2017-02-14 Conjugado amiloide y usos y procedimientos del mismo

Country Status (22)

Country Link
US (3) US20190030127A1 (es)
EP (1) EP3390426B1 (es)
JP (1) JP6689993B2 (es)
KR (1) KR102301961B1 (es)
CN (1) CN108633278B (es)
AU (1) AU2017221070B2 (es)
BR (1) BR112018016016A2 (es)
CA (1) CA3012417C (es)
CL (1) CL2018002004A1 (es)
CO (1) CO2018007557A2 (es)
DK (1) DK3390426T3 (es)
ES (2) ES2571055B1 (es)
IL (1) IL260639B2 (es)
MX (1) MX2018008885A (es)
MY (1) MY184763A (es)
PL (1) PL3390426T3 (es)
PT (1) PT3390426T (es)
RU (1) RU2712750C1 (es)
SG (1) SG11201806158YA (es)
SI (1) SI3390426T1 (es)
WO (1) WO2017140656A1 (es)
ZA (1) ZA201804842B (es)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100068214A1 (en) * 2006-12-21 2010-03-18 Monash University Identification of Candidate Vaccine Antigens from Dichelobacter Nodosus
WO2010136487A1 (en) * 2009-05-26 2010-12-02 Araclon Biotech S.L. Albumin-amyloid peptide conjugates and uses thereof
US20120244159A1 (en) * 1997-04-09 2012-09-27 Intellect Neurosciences Inc. Specific Antibodies To Amyloid Beta Peptide, Pharmaceutical Compositions And Methods Of Use Thereof
US20130230545A1 (en) * 2008-06-12 2013-09-05 Markus Mandler Compounds for treating beta-amyloidoses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246178B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
WO2005058940A2 (en) * 2003-12-17 2005-06-30 Wyeth Immunogenic peptide carrier conjugates and methods of producing same
WO2005072777A2 (en) * 2004-01-28 2005-08-11 Curix Aps Conjugates of amyloid proteins as vaccines for amyloid-related diseases
WO2006121656A2 (en) * 2005-05-05 2006-11-16 Merck & Co., Inc. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
US20110092445A1 (en) * 2008-07-25 2011-04-21 Abbott Laboratories Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses
CN102300582A (zh) * 2009-01-30 2011-12-28 阿尔法贝塔公司 用于治疗阿尔茨海默病的化合物和方法
MX2012011340A (es) * 2010-03-29 2012-11-16 Novartis Ag Composicion que comprende el peptido amiloide beta 1-6acoplado a una particula similar a virus y un auxiliar.
US20130164217A1 (en) * 2011-12-21 2013-06-27 Meso Scale Technologies, Llc Method of diagnosing, preventing and/or treating dementia & related disorders
MX2016010838A (es) 2014-02-28 2016-11-17 Affiris Ag Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9).

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244159A1 (en) * 1997-04-09 2012-09-27 Intellect Neurosciences Inc. Specific Antibodies To Amyloid Beta Peptide, Pharmaceutical Compositions And Methods Of Use Thereof
US20100068214A1 (en) * 2006-12-21 2010-03-18 Monash University Identification of Candidate Vaccine Antigens from Dichelobacter Nodosus
US20130230545A1 (en) * 2008-06-12 2013-09-05 Markus Mandler Compounds for treating beta-amyloidoses
WO2010136487A1 (en) * 2009-05-26 2010-12-02 Araclon Biotech S.L. Albumin-amyloid peptide conjugates and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAFI, K. et al. "Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines". MOLECULAR IMMUNOLOGY. Enero 2009. Vol. 46, N°. 3, páginas 448 - 456; todo el documento. *

Also Published As

Publication number Publication date
BR112018016016A2 (pt) 2018-12-18
WO2017140656A1 (en) 2017-08-24
JP6689993B2 (ja) 2020-04-28
DK3390426T3 (da) 2019-09-30
MX2018008885A (es) 2018-11-09
IL260639B1 (es) 2023-02-01
KR102301961B1 (ko) 2021-09-14
CA3012417A1 (en) 2017-08-24
RU2712750C1 (ru) 2020-01-31
CA3012417C (en) 2022-05-31
ZA201804842B (en) 2019-05-29
NZ744411A (en) 2022-03-25
MY184763A (en) 2021-04-21
AU2017221070A1 (en) 2018-08-09
PT3390426T (pt) 2019-10-10
IL260639B2 (en) 2023-06-01
CL2018002004A1 (es) 2018-09-28
ES2571055B1 (es) 2016-12-28
AU2017221070B2 (en) 2021-04-01
SI3390426T1 (sl) 2019-11-29
EP3390426A1 (en) 2018-10-24
US20220184178A1 (en) 2022-06-16
US20190030127A1 (en) 2019-01-31
CO2018007557A2 (es) 2018-07-31
JP2019512001A (ja) 2019-05-09
PL3390426T3 (pl) 2020-05-18
US20200246430A1 (en) 2020-08-06
CN108633278B (zh) 2022-09-13
IL260639A (es) 2018-09-20
EP3390426B1 (en) 2019-06-26
KR20180118126A (ko) 2018-10-30
SG11201806158YA (en) 2018-08-30
CN108633278A (zh) 2018-10-09
ES2747899T3 (es) 2020-03-12

Similar Documents

Publication Publication Date Title
EA202190983A1 (ru) Новое антитело к с-kit
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
PH12021500014A1 (en) Fused ring compounds
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
CL2020002841A1 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
UY37592A (es) Compuestos inhibidores del vih
MX2021001957A (es) Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
EA201792616A1 (ru) Средства, пути применения и способы лечения синуклеопатии
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
MX2019009117A (es) Anticuerpos anti alfa-sinucleina y usos de los mismos.
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
CR20190208A (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
EA201900562A1 (ru) Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты
CO2022002374A2 (es) Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
EA202091804A1 (ru) Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
ES2571055A1 (es) Conjugado amiloide y usos y procedimientos del mismo
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
CL2022001167A1 (es) Tratamiento de trastornos hepáticos
EA201992883A1 (ru) АНТИТЕЛА К TrkB

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2571055

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20161228